'김갑성' 기자의 전체기사
-
Getinge Interim Report April-June 2025: Continuing positive tren…
GOTHENBURG, Sweden, July 18, 2025 -- "The positive start to 2025 continued in the second quarter, with stable organic growth in order intake and sales, and our margins strengthened despite strong headwinds from tariffs and negative currency effects," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 4.1% while order intake rose by 4.4% organically. Business area Acute Care Therapies continues to be successful in handling the increased demand for ventilators, and the order intake in ECLS consumables remains high. The
- 김갑성 기자
- 2025-07-18 14:29
-
The World Federation of Neurology to Host Global Webinar Un…
LONDON, July 18, 2025 -- On July 22, the World Federation of Neurology (WFN) will celebrate its 12th annual World Brain Day, with the theme "Brain Health for All Ages." The official event of World Brain Day is a webinar, open to the public, taking place at 1:00 p.m. BST. World Brain Day is an annual event uniting the global community to protect and promote healthy brains. The webinar serves as a global call to action for both individuals, healthcare providers, non-governmental organizations, community leaders, policy-makers, and institutions to share meaningf
- 김갑성 기자
- 2025-07-18 14:00
-
Bowtie Secures Series C Fundraising From Sun Life
[ 메디채널 김갑성 기자 ] New Funding Fuels Growth in Medical Insurance and Innovation in Preventive Healthcare HONG KONG, July 18, 2025 -- Bowtie, Hong Kong's first virtual insurer[1], is proud to announce securing up to US$70 million in its Series C funding round. Led by Sun Life Hong Kong Limited ("Sun Life"), this marks the largest funding round for digital health insurers in Asia with a direct-to-consumer model. Bowtie continues to lead in Hong Kong's digital insurance market, ranking first in the direct channel[2], and securing the 9th position across all dist
- 김갑성 기자
- 2025-07-18 11:25
-
MFDS Clears DeepQure's HyperQure™ for Clinical Trial in Atrial Fib…
SEOUL, South Korea, July 18, 2025 -- DeepQure announced today that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical trial of HyperQure™ RDM System, the company's novel laparoscopic renal denervation (RDN) system, for the treatment of atrial fibrillation (AF). The trial is designed to evaluate the safety and efficacy of laparoscopic RDN in patients with recurrent AF following pulmonary vein isolation (PVI) and resistant hypertension. It will be conducted as a multicenter, prospective, single-arm, open-label exploratory study. HyperQure™ is a next-gene
- 김갑성 기자
- 2025-07-18 10:59
-
Fujitsu and Acer Medical trial AI service that assesses future…
[ 메디채널 김갑성 기자 ] KAWASAKI, Japan and NEW TAIPEI CITY, July 18, 2025 -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uva
- 김갑성 기자
- 2025-07-18 09:34
-
Lifezoom Launches Veyra Series: Flexible Red Light Thera…
NEW YORK, July 17, 2025 -- Lifezoom, a pioneer of red light therapy in the USA, is excited to expand with the new industry-leading Veyra Series, red light therapy panels that mix creativity, adaptability, and health-focused design. Now, with two launch products, Veyra C and Veyra S, this versatile red light technology, built on a flexible silicone base material, is available throughout the U.S and Europe at the starting price of $249. After years of research and development, the Lifezoom engineering team from Iowa's hardworking community has brought to market a product that not
- 김갑성 기자
- 2025-07-17 21:03
-
Co-PSMA trial: Recruitment successfully completed
SYDNEY, July 17, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent's Hospital Sydney has now completed study enrolment, with all participants having been imaged. The study is evaluating the performance of Clarity's diagnostic product, 64Cu-SAR-b
- 김갑성 기자
- 2025-07-17 21:01
-
RapidClaims Receives Frost & Sullivan's 2025 North American He…
[ 메디채널 김갑성 기자 ] Recognized for driving operational efficiency and accelerating customer acquisition through AI-powered automation and a highly adaptive deployment model SAN ANTONIO, July 17, 2025 -- Frost & Sullivan is pleased to announce that RapidClaims has been recognized with the 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition in the healthcare IT industry for its outstanding achievements in product innovation, operational excellence, and customer-centric design in the revenue cycle management (RCM) space. This recognition
- 김갑성 기자
- 2025-07-17 21:00
-
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuva…
Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market "Our SKYCellflu platform with our adjuvanted vaccine experience will lay a strong foundation for future success." SEONGNAM, South Korea, July 17, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has submitted an In
- 김갑성 기자
- 2025-07-17 19:00
-
Five-year Pharmacovigilance study by NTC confirms safety of…
MILAN, July 17, 2025 -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of inflammation and prevention of infection following cataract surgery in adults. The study was submitted when nearly 4 million patients across about 60 countries worldwide were treated with this drug. Conducted by Italian researchers and supported by NTC, the study analyzed public safety data registered in
- 김갑성 기자
- 2025-07-17 17:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-21_THU
2025-08-20_WED
- Global Times: Development opportunities, potential and advantages should be better used 23:58
- First IPO Under GIFT City's IFSC Regime - DRHP Filed; Executive Education Platform Leads the Charge 22:19
- Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning 22:14
- TGE alongside with AMTD Obtain Successful Court Decisions against Unauthorised and Infringing Activities in Austria 21:55
- Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year 21:41
- FOSSIL AND 2025-2026 GLOBAL BRAND AMBASSADOR NICK JONAS RELEASE EXCLUSIVE "MACHINE LUXE" CAPSULE 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 21일 06시 40분